Free Trial

Immunome (IMNM) News Today

Immunome logo
$14.53 +0.80 (+5.83%)
(As of 06:08 PM ET)
Immunome, Inc. stock logo
Point72 Asset Management L.P. Buys 85,580 Shares of Immunome, Inc. (NASDAQ:IMNM)
Point72 Asset Management L.P. increased its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 22.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 470,647 shares of the company's stock after purchasing an additional 85,580 shares during the
Immunome, Inc. stock logo
Janus Henderson Group PLC Has $50.97 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)
Janus Henderson Group PLC raised its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 10.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,488,121 shares of the company'
Immunome Inc.
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been given an average rating of "Buy" by the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that hav
Immunome, Inc. stock logo
Robert Lechleider Buys 15,805 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Robert Lechleider purchased 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Immunome, Inc. stock logo
Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CTO Purchases 21,000 Shares of Stock
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CTO Philip Tsai purchased 21,000 shares of the firm's stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) CEO Acquires $630,183.78 in Stock
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The shares were bought at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Immunome files to sell 1.8M shares of common stock for holders
Immunome, Inc. stock logo
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM)
Victory Capital Management Inc. raised its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,785 shares of the company's stock after
Immunome (IMNM) Receives a Buy from J.P. Morgan
Immunome, Inc. stock logo
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs
Immunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 EPS estimates for shares of Immunome in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($2.23) per share for the year,
Immunome, Inc. stock logo
Wedbush Has Positive Forecast for Immunome FY2024 Earnings
Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Wedbush upped their FY2024 earnings estimates for Immunome in a report released on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will earn ($2.11) per share for the year, up from their pr
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst Downgrade
Immunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst Downgrade
Immunome, Inc. stock logo
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00
Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Thursday.
Immunome initiated with an Overweight at Stephens
Analyst Expectations For Immunome's Future
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy?
Immunome (NASDAQ:IMNM) Shares Gap Up - Time to Buy?
Immunome, Inc. stock logo
Stephens Begins Coverage on Immunome (NASDAQ:IMNM)
Stephens began coverage on Immunome in a research note on Friday. They set an "overweight" rating and a $30.00 price target for the company.
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Trading Up 8.7% - Here's What Happened
Immunome (NASDAQ:IMNM) Trading Up 8.7% - Still a Buy?
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts
Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages th
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 10,920,000 shares, a decline of 15.2% from the September 30th total of 12,880,000 shares. Currently, 22.3% of the shares of the stock are short sold. Based on an average trading volume of 649,500 shares, the days-to-cover ratio is currently 16.8 days.
Wedbush Remains a Buy on Immunome (IMNM)
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Stock Rating Reaffirmed by Wedbush
Wedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a report on Friday.
Immunome, Inc. stock logo
Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM)
Cubist Systematic Strategies LLC reduced its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the company's stock after sel
Immunome, Inc. stock logo
The Manufacturers Life Insurance Company Grows Stock Position in Immunome, Inc. (NASDAQ:IMNM)
The Manufacturers Life Insurance Company increased its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 52.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 166,928 shares of the company's stock
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Trading Down 6.1% - Time to Sell?
Immunome (NASDAQ:IMNM) Stock Price Down 6.1% - Should You Sell?
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Trading Up 3.5% - Here's What Happened
Immunome (NASDAQ:IMNM) Stock Price Up 3.5% - Should You Buy?
Immunome, Inc. stock logo
Squarepoint Ops LLC Sells 45,843 Shares of Immunome, Inc. (NASDAQ:IMNM)
Squarepoint Ops LLC decreased its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 38.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 73,929 shares of the company's stock after selling 45,843 shares during the period. Squarepoi
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Buy" from Analysts
Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages th
Immunome, Inc. stock logo
Cubist Systematic Strategies LLC Sells 54,117 Shares of Immunome, Inc. (NASDAQ:IMNM)
Cubist Systematic Strategies LLC cut its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,421 shares of the company's st
Immunome, Inc. stock logo
Immunome, Inc. (NASDAQ:IMNM) Stock Holdings Cut by Point72 Asset Management L.P.
Point72 Asset Management L.P. lessened its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 76.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 385,067 shares of the company's stock after selling 1,256,833 shares during t
Immunome, Inc. stock logo
Immunome (NASDAQ:IMNM) Shares Down 4.7%
Immunome (NASDAQ:IMNM) Stock Price Down 4.7%
Immunome, Inc. stock logo
Axa S.A. Invests $2.17 Million in Immunome, Inc. (NASDAQ:IMNM)
Axa S.A. acquired a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,688 shares of the company's stock, valued at approximately $2,174,000. Axa
Immunome, Inc. stock logo
Northeast Financial Consultants Inc Buys Shares of 72,953 Immunome, Inc. (NASDAQ:IMNM)
Northeast Financial Consultants Inc purchased a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 72,953 shares of the company's stock, valued a
Immunome, Inc. stock logo
Marshall Wace LLP Has $20.73 Million Stake in Immunome, Inc. (NASDAQ:IMNM)
Marshall Wace LLP lifted its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 228.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,713,325 shares of the company's stock after buying an addition
IMNM Jan 2025 17.500 call
Get Immunome News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.

The indicator behind Nvidia’s rally has a new prospect (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

IMNM Media Mentions By Week

IMNM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMNM
News Sentiment

0.77

0.68

Average
Medical
News Sentiment

IMNM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMNM Articles
This Week

3

4

IMNM Articles
Average Week

Get Immunome News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:IMNM) was last updated on 12/9/2024 by MarketBeat.com Staff
From Our Partners